About Syngene
Syngene is a company based in Bengaluru (India) founded in 1993. Syngene has raised $85.89 million across 3 funding rounds from investors including Goldman Sachs, Morgan Stanley and GE Capital. The company has 8,230 employees as of March 31, 2024. Syngene has completed 1 acquisition, including Strand Life Sciences. Syngene operates in a competitive market with competitors including Abzena, Patheon, Piramal Group, Maravai Life Sciences and LakePharma, among others.
- Headquarter Bengaluru, India
- Employees 8230 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Syngene International Ltd.
-
Annual Revenue
$425.59 M (USD)4.31as on Mar 31, 2025
-
Net Profit
$58.06 M (USD)-2.71as on Mar 31, 2025
-
EBITDA
$123.49 M (USD)-2.58as on Mar 31, 2025
-
Total Equity Funding
$85.89 M (USD)
in 3 rounds
-
Latest Funding Round
$131.23 M (USD), Post-IPO
Feb 02, 2023
-
Investors
Goldman Sachs
& 7 more
-
Employee Count
8230
as on Mar 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Syngene
Syngene is a publicly listed company on the NSE with ticker symbol SYNGENE in India, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Syngene
Unlock access to complete
Unlock access to complete
Funding Insights of Syngene
Syngene has successfully raised a total of $85.89M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $131.23 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Syngene
Syngene has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Goldman Sachs, Morgan Stanley and GE Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sovereign wealth is managed and private equity investments are facilitated.
|
Locked | Locked | Locked | |
|
Investment banking services are delivered across multiple financial sectors.
|
Locked | Locked | Locked | |
|
Investment strategies are provided across diverse asset classes and markets.
|
Locked | Locked | Locked |
Investor details for Syngene
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Syngene
Syngene has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Strand Life Sciences.
Investment portfolio details for Syngene
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for Syngene
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Syngene
Detailed financials for Syngene
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Syngene Comparisons
Peer comparison for Syngene
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Syngene
Syngene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abzena, Patheon, Piramal Group, Maravai Life Sciences and LakePharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of antibody discovery, cell line development, and bio analytics services
|
|
| Locked | Locked | Locked |
Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry
|
|
| Locked | Locked | Locked |
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
|
|
| Locked | Locked | Locked |
Provides enabling tools and services in the life sciences research and bio-production industries
|
|
| Locked | Locked | Locked |
Provider of drug discovery on molecular biology, viral vectors and cell & protein engineering
|
Detailed competitors of Syngene
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Syngene
Complete news archive for Syngene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Syngene
Syngene was founded in 1993 and raised its 1st funding round 19 years after it was founded.
Syngene is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Jonathan Hunt is the current CEO of Syngene.
Syngene is a funded company, having raised a total of $85.89M across 3 funding rounds to date.
As of Mar 31, 2024, the latest employee count at Syngene is 8,230.
Annual revenue of Syngene is $425.59M as on Mar 31, 2025.
Syngene was founded in 1993 in Bengaluru, India, as a provider of contract research and manufacturing in the biotechnology sector. Discovery services are extended across small molecules, large molecules, antibody-drug conjugates, and oligonucleotides. Biological operations encompass recombinant DNA engineering, cell line development, protein sciences, assay biology, DMPK, in vivo pharmacology, and toxicology. Synthetic and medicinal chemistry support is integrated with biological and DMPK elements for comprehensive solutions.
Syngene's top competitors include Abzena, Grand River Aseptic Manufacturing and Patheon.
Yes, Syngene is publicly traded on NSE under the ticker symbol SYNGENE.
Syngene has made 1 acquisition, including Strand Life Sciences.
Syngene has 8 investors. Key investors include Goldman Sachs, Morgan Stanley, GE Capital, Caisse de depot et placement du Quebec, and GIC.
The ticker symbol of Syngene is SYNGENE on NSE.